Incyte strikes up to $2 billion deal for Star Therapeutics' subsidiary
Incyte said on Monday it has agreed to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, in a deal worth up to $2 billion, expanding its pipeline for blood disorder therapies.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Sahal Muhammed and Vijay Kishore)
Copyright Reuters or USA Today Network via Reuters Connect
This story was originally published June 8, 2026 at 4:07 AM.